| Date | Title | Description | |
|---|---|---|---|
| 12 Apr 2021 | On business and financial situation | The Company releases the press release related to its participation in the manufacture of the active substance of Moderna’s COVID-19 vaccine. | Download |
| 02 Mar 2021 | On business and financial situation | The Company releases an update of the regulatory processes of its long-acting injectable antipsychotic, Doria®, both in Europe and the United States | Download |
| 02 Mar 2021 | On business and financial situation | The Company releases a presentation related to an update of the regulatory processes of its long-acting injectable antipsychotic, Doria®, both in Europe and the United States | Download |
| 24 Feb 2021 | About corporate governance | The Company informs about the agreements adopted by the Board of Directors | Download |
| 27 Nov 2020 | On business and financial situation | The Company publishes the results of the PRISMA-3 study of the efficacy and safety of Doria® in schizophrenic patients in the journal npj Schizophrenia | Download |
Pages
| Date | Title | Description | |
|---|---|---|---|
| 26 Jun 2023 | Other relevant information | The Company informs about the dividends payment | Download |
| 14 Jun 2023 | Announcement of general shareholders’ meeting | ROVI releases the information related to its General Shareholders Meeting. | Download |
| 31 May 2023 | Other relevant information | ROVI informs about the news items that have appeared in several media today regarding ROVI’s receipt of government grants | Download |
| 10 May 2023 | Announcement of General Shareholders’ Meeting | ROVI releases the information related to its General Shareholders Meeting | Download |
| 10 Apr 2023 | Liquidity and counterparty agreements | Liquidity contract: transactions conducted in the first quarter of 2023 | Download |